Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

EXPLAINED: 45 | Vintage Vibes

Older Americans to pay less for some drug treatments as drugmakers penalized for big price jumps

Hundreds of thousands of older Americans could pay less for outpatient drug treatments beginning early next year

The Independent UK · Dec 14, 2023

Vivek Ramaswamy spins conspiracy theories at bad-tempered CNN town hall

Republican presidential candidate sparred with host Abby Phillip at Iowa event

The Independent UK · Dec 14, 2023

Pfizer Shares Tumble On Disappointing 2024 Profit Outlook

Pfizer issued a disappointing 2024 forecast Wednesday, denting shares as the company navigates a profound plunge in sales tied to the Covid-19 pandemic.

International Business Times · Dec 13, 2023

From analysis to the latest developments in health,
read the most diverse news in one place.

Supreme Court to Consider Restrictions on Abortion Drug Mifepristone

The Supreme Court is reconsidering the accessibility of popular abortion drug, Mifepristone, a high-stakes case with potential electoral repercussions.

Committee recommends curbs on freebies doled out by pharma companies

Committee recommends revising UCPMP to prohibit CMEs in foreign locations, disclose price of gifts to doctors, and make money received by doctors from pharma cos for research taxable.

The Hindu · Dec 13, 2023

FDA Seeks Power for Eyedrops Recalls Amid Foreign Inspections Woes

U.S. health officials grapple with inadequate inspection of overseas eyedrop factories, leading to recalls of potentially dangerous products.

Safer eyedrops will require new FDA powers and resources, experts say

Repeated recalls of eyedrops are drawing new attention to the limited powers U.S. regulators have to oversee medical products made overseas

The Independent UK · Dec 13, 2023

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca buys US vaccine company in $1.1bn deal

Britain’s biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business

The Guardian - UK · Dec 12, 2023

Citius Pharmaceuticals (CTXR) Earnings Watch: Pharma Stock Signals for Investors

Citius Pharmaceuticals (CTXR) has been making significant progress in its pipeline, garnering investors' attention. However, considering that CTXR is an unprofitable and pre-revenue business, is it worth investing now as the company prepares to report quarterly results? Keep reading.

StockNews.com · Dec 11, 2023

3 Pharma Powerhouses to Boost Your Year-End Investments

Backed by an ever-growing need for chronic disease treatments, rapid investments in research and development, and widespread integration of technology, the pharmaceutical sector is anticipated to flourish. Thus, as we approach the end of 2023, three solid pharma stocks, GoodRx Holdings (GDRX), CytomX Therapeutics (CTMX), and Neurocrine Biosciences (NBIX), could…

StockNews.com · Dec 11, 2023

3 Pharma Stocks Flashing 'Buy' Signals in December

The pharmaceutical industry is well-positioned for robust growth, driven by growing healthcare expenditure globally and the rapid adoption of digital technologies. Given the industry’s tailwinds, fundamentally strong pharma stocks, Collegium Pharmaceutical (COLL), Eton Pharmaceuticals (ETON), and GSK plc (GSK) could be ideal buys this month. Continue Reading….

StockNews.com · Dec 8, 2023

DeSantis raises eyebrows by telling GOP debate his favourite president is Calvin Coolidge

‘He’s one of the few presidents that got almost everything right. He understood the proper role of the federal government under the Constitution,’ DeSantis says

The Independent UK · Dec 7, 2023

DCA busts spurious anti-cancer drug racket, ₹4.35 crore stock seized

The Hindu · Dec 5, 2023

The Guardian view on cystic fibrosis treatments: a rollercoaster ride for the sick

Editorial: Patients are facing shorter lives as drug companies are demanding prices that health services here and in other countries cannot pay

The Guardian - UK · Dec 5, 2023

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times · Dec 4, 2023

Divided US High Court Hears Challenge To $6bn Purdue Opioid Settlement

The US Supreme Court appeared divided on Monday as it heard a challenge to Purdue Pharma's $6 billion opioids settlement immunizing the Sackler family that controlled the drugmaker from future litigation.

Caixin Global · Dec 4, 2023

WuXi Biologics Plunges on Concerns over Cooling Biotech Market

Leading Chinese drug company estimates $100 million net loss in 2023 as biotech funding slows and Covid related income falls

The Independent UK · Dec 4, 2023

The Sackler family wants protection from opioid lawsuits. Will the Supreme Court grant it?

A bankruptcy case before the Supreme Court could grant the Sackler family immunity from opioid-related civil cases Ariana Baio reports

AAP · Dec 4, 2023

Opioid users to get greater access to overdose drug

Access to an overdose reversal drug has been expanded in Victoria, almost 18 months after the federal government allowed it.

Get all your
news in one place.

100's of premium titles.
One news app.

AAP · Dec 4, 2023

Blackmores unit allegedly fired health whistleblower

An employee of a Blackmores subsidiary has claimed the firm terminated him instead of dealing with health concerns raised about two of its vitamin products.

International Business Times · Dec 4, 2023

US High Court To Hear Challenge To $6bn Purdue Opioid Settlement

The US Supreme Court is to hear a challenge on Monday to Purdue Pharma's $6 billion opioids settlement immunizing the family that controlled the drugmaker from future litigation.

StockNews.com · Dec 1, 2023

3 Pharma Stocks Navigating Future Investments - Buy Now

The pharmaceutical industry is evolving with changing consumer behavior, rapid adoption of digital solutions, and global expansion. Hence, fundamentally strong pharma stocks Zoetis (ZTS), Wave Life Sciences (WVE), and Johnson & Johnson (JNJ) might be solid investments now. Read more….

StockNews.com · Dec 1, 2023

Are These 3 Pharma Stocks a Buy or Hold Opportunity for December?

The pharmaceutical industry looks well-positioned for long-term growth. So, let us analyze pharma stocks Procaps Group (PROC), Voyager Therapeutics (VYGR) and Organon & Co. (OGN) to identify whether they are a Buy or Hold. Read on.

AAP · Nov 28, 2023

Carr calls for courage ahead of next drug summit

Courage remains vital in drug policy, former NSW premier Bob Carr says as he and fellow players in a landmark drug summit press for more change.

StockNews.com · Nov 28, 2023

3 Pharma Stocks on the Rise - It's Time to Buy Now

The pharma industry’s long-term solid outlook is driven by steady demand for drugs due to the rising frequency of chronic conditions and growing geriatric population coupled with rapid technological innovations. Hence, quality pharma stocks, CytomX Therapeutics (CTMX), Eton Pharmaceuticals (ETON), and GSK (GSK), might be solid investments now for potential…

The Hindu · Nov 28, 2023

Indian drug manufacturers benefit from Big Pharma interest beyond China

Drugmakers shift reliance from China to India, benefiting Indian CDMOs. Western pharma companies are seeking to limit reliance on Chinese contractors, leading to increased interest in Indian CDMOs.

1 … 44 45 46 47

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Justice Department

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.